公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial | Soo, Ross A; Huat Tan, Eng; Hayashi, Hidetoshi; Seto, Takashi; CHIA-CHI LIN ; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Liu, Geoffrey; Abbattista, Antonello; Martini, Jean-François; Hooi Wong, Chew; Toffalorio, Francesca; Solomon, Benjamin J | Lung cancer (Amsterdam, Netherlands) | 9 | | |
2022 | Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC | Wu, Yi-Long; Lu, Shun; CHIH-HSIN YANG ; Zhou, Jianying; Seto, Takashi; Ahn, Myung-Ju; Su, Wu-Chou; Yamamoto, Noboru; Kim, Dong-Wan; Paolini, Jolanda; Usari, Tiziana; Iadeluca, Laura; Wilner, Keith D; Goto, Koichi | JTO clinical and research reports | 4 | 0 | |
2015 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. | Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan | J. Clin. Oncol. | | | |